obesity news from FierceBiotech
News'Brown fat' may be a key to curing obesity
By manipulating levels of the protein BMP-7, Harvard Medical School researchers were able to generate a larger store of "brown" fat cells that burn calories--a pathway that could be used to pursue Read more...
Developers advancing a new slate of weight loss drugs
The Wall Street Journal reviews the slate of mid-stage therapies in clinical trials for obesity. While the market for new therapies is huge -- no pun intended - the challenges involved in developing Read more...
Biotechs discuss obesity therapies at BIO
No fewer than 20 drug companies are working to find a drug to treat obesity. About $30 billion is spent each year on weight loss, but only $200 million of that is spent on prescription drugs. At the Read more...
Sanofi: Acomplia demonstrates better glucose control
Sanofi-Aventis said that a trial of Acomplia showed a significant improvement in glucose control in comparison to insulin among patients with type 2 diabetes. Glucose control was three times more Read more...
Arena touts safety profile of obesity drug
The analysts were buzzing this morning about Arena Pharmaceuticals' chances of a major partnership pact for its obesity drug Read more...
Merck inks diabetes deal with fledgling Marcadia
Fledgling developer Marcadia Biotech has lined itself up with the pharmaceutical giant Merck in a licensing deal on the Indianapolis-based developer's work in diabetes. Marcadia has been working with Read more...
ALSO NOTED: Promacta gets priority review; GTx drug hits endpoint; Alexza touts IIa data; and much more...
> Glaxo's Promacta, a bleeding disorder drug, will be given a priority review by the FDA. Read more...
ALSO NOTED: U.K. calls for halt to HIV study; Cadence to raise $49.3M; and much more...
> The U.K.'s Medical Research Council has advised Indevus Pharmaceuticals to close the high-dose arm of it's Phase III HIV study. Read more...
FDA overhauls trial design with new suicide standard
The FDA has quietly engineered the biggest change-up in the way many clinical trials are designed since the early '90s. Developers working in a range of fields including obesity, epilepsy, smoking Read more...
FDA committee rejects Solvay's tedisamil
An FDA expert panel has unanimously turned thumbs down on Solvay's tedisamil for atrial fibrillation. The experts said they would need more and better data before they could change their decision. Read more...
| Press ReleasesPRESS RELEASE: Drug Dosages Often Incorrect For Obese Patients Drug Dosages Often Incorrect For Obese Patients ScienceDaily (Nov. 16, 2007) — As if severely overweight people didn't already have enough health concerns, experts are raising another red flag -- Read more... PRESS RELEASE: Food Restriction Increases Dopamine Receptor Levels in Obese Rats Food Restriction Increases Dopamine Receptor Levels in Obese Rats Evidence for interplay of brain's "reward" chemical with availability of food in obesity UPTON, NY - A brain-imaging study Read more... PRESS RELEASE: ‘Knocking Out’ Cell Receptor May Help Block Fat Deposits in Tissues, Prevent Weight Gain ‘Knocking Out’ Cell Receptor May Help Block Fat Deposits in Tissues, Prevent Weight Gain Cincinnati—University of Cincinnati (UC) pathologists have identified a new molecular target that one Read more... PRESS RELEASE: Arena Pharmaceuticals to Continue Obesity Study After Safety Review Arena Pharmaceuticals to Continue Obesity Study After Safety Review SAN DIEGO, Sept. 11 -- Arena Pharmaceuticals announced today that an independent Echocardiographic Data Safety Monitoring Board Read more... |
Get more obesity coverage at:
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets